Avoiding Time-Related Biases: A Feasibility Study on Antidiabetic Drugs and Pancreatic Cancer Applying the Parametric g-Formula to a Large German Healthcare Database

References

• Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care. 2012;35(12):2665–2673. doi:10.2337/dc12-078823173135
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S. Time-related biases in pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2020;29(9):1101–1110. doi:10.1002/pds.508332783283
   PubMed Web of Science ®Google Scholar
• Hernán MA, Hernández-Díaz S, Robins JM. Randomized trials analyzed as observational studies. Ann Intern Med. 2013;159(8):560–562.24018844
   PubMed Web of Science ®Google Scholar
• Hernan MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758–764. doi:10.1093/aje/kwv25426994063
   PubMed Web of Science ®Google Scholar
• Daniel RM, Cousens SN, De Stavola BL, Kenward MG, Sterne JA. Methods for dealing with time-dependent confounding. Stat Med. 2013;32(9):1584–1618. doi:10.1002/sim.568623208861
   PubMed Web of Science ®Google Scholar
• Young JG, Cain LE, Robins JM, O’Reilly EJ, Hernan MA. Comparative effectiveness of dynamic treatment regimes: an application of the parametric g-formula. Stat Biosci. 2011;3(1):119–143. doi:10.1007/s12561-011-9040-724039638
   PubMedGoogle Scholar
• Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism. 2013;62(7):922–934. doi:10.1016/j.metabol.2013.01.01423419783
   PubMed Web of Science ®Google Scholar
• Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010;3(11):1451–1461. doi:10.1158/1940-6207.CAPR-10-015720947488
   PubMed Web of Science ®Google Scholar
• Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One. 2013;8(8):e71583. doi:10.1371/journal.pone.007158323936520
   PubMed Web of Science ®Google Scholar
• Suissa S, Azoulay L. Metformin and cancer: mounting evidence against an association. Diabetes Care. 2014;37(7):1786–1788. doi:10.2337/dc14-050024963109
   PubMed Web of Science ®Google Scholar
• Yang XL, Ma RC, So WY, Kong AP, Xu G, Chan JC. Addressing different biases in analysing drug use on cancer risk in diabetes in non-clinical trial settings–what, why and how? Diabetes Obes Metab. 2012;14(7):579–585. doi:10.1111/j.1463-1326.2011.01551.x22171706
   PubMed Web of Science ®Google Scholar
• Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs–FDA and EMA assessment. N Engl J Med. 2014;370(9):794–797. doi:10.1056/NEJMp131407824571751
   PubMed Web of Science ®Google Scholar
• Tseng CH, Lee KY, Tseng FH. An updated review on cancer risk associated with incretin mimetics and enhancers. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2015;33(1):67–124. doi:10.1080/10590501.2015.100349625803196
   PubMed Web of Science ®Google Scholar
• Stoian AP, Sachinidis A, Stoica RA, Nikolic D, Patti AM, Rizvi AA. The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes. Metabolism. 2020;109:154295. doi:10.1016/j.metabol.2020.15429532553739
   PubMed Web of Science ®Google Scholar
• Dankner R, Roth J. More recent, better designed studies have weakened links between antidiabetes medications and cancer risk. Diabet Med. 2020;37(2):194–202. doi:10.1111/dme.1417931769894
   PubMed Web of Science ®Google Scholar
• Rehman MB, Tudrej BV, Soustre J, et al. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: meta-analysis of placebo-controlled randomized clinical trials. Diabetes Metab. 2017;43(1):48–58. doi:10.1016/j.diabet.2016.09.00527745828
   PubMed Web of Science ®Google Scholar
• Dicembrini I, Montereggi C, Nreu B, Mannucci E, Monami M. Pancreatitis and pancreatic cancer in patients treated with Dipeptidyl Peptidase-4 inhibitors: an extensive and updated meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2020;159:107981. doi:10.1016/j.diabres.2019.10798131870827
   PubMed Web of Science ®Google Scholar
• Lee M, Sun J, Han M, et al. Nationwide trends in pancreatitis and pancreatic cancer risk among patients with newly diagnosed type 2 diabetes receiving dipeptidyl peptidase 4 inhibitors. Diabetes Care. 2019;42(11):2057–2064. doi:10.2337/dc18-219531431452
   PubMed Web of Science ®Google Scholar
• Boniol M, Franchi M, Bota M, et al. Incretin-based therapies and the short-term risk of pancreatic cancer: results from two retrospective cohort studies. Diabetes Care. 2018;41(2):286–292. doi:10.2337/dc17-028029146599
   PubMed Web of Science ®Google Scholar
• Pfeiffer AFH, Klein HH. Therapie des diabetes mellitus type 2. Dtsch Arztebl Int. 2014;111(5):69–82.24612534
   PubMed Web of Science ®Google Scholar
• Pigeot I, Ahrens W. Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations. Pharmacoepidemiol Drug Saf. 2008;17(3):215–223. doi:10.1002/pds.154518200610
   PubMed Web of Science ®Google Scholar
• Young JG, Stensrud MJ, Tchetgen Tchetgen EJ, Hernán MA. A causal framework for classical statistical estimands in failure-time settings with competing events. Stat Med. 2020;39(8):1199–1236. doi:10.1002/sim.847131985089
   PubMed Web of Science ®Google Scholar
• Sharma A, Smyrk TC, Levy MJ, Topazian MA, Chari ST. Fasting blood glucose levels provide estimate of duration and progression of pancreatic cancer before diagnosis. Gastroenterology. 2018;155(2):490–500.e492. doi:10.1053/j.gastro.2018.04.02529723506
   PubMed Web of Science ®Google Scholar
• Sato K, Hikita H, Myojin Y, et al. Hyperglycemia enhances pancreatic cancer progression accompanied by elevations in phosphorylated STAT3 and MYC levels. PLoS One. 2020;15(7):e0235573. doi:10.1371/journal.pone.023557332609742
   PubMed Web of Science ®Google Scholar
• Stolzenberg-Solomon RZ, Graubard BI, Chari S, et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA. 2005;294(22):2872–2878. doi:10.1001/jama.294.22.287216352795
   PubMed Web of Science ®Google Scholar
• Sadr-Azodi O, Gudbjornsdottir S, Ljung R. Pattern of increasing HbA1c levels in patients with diabetes mellitus before clinical detection of pancreatic cancer - a population-based nationwide case-control study. Acta Oncol. 2015;54(7):986–992. doi:10.3109/0284186X.2015.100640225734801
   PubMed Web of Science ®Google Scholar
• Danaei G, Robins JM, Young JG, Hu FB, Manson JE, Hernán MA. Weight loss and coronary heart disease: sensitivity analysis for unmeasured confounding by undiagnosed disease. Epidemiology. 2016;27(2):302–310.26628428
   PubMed Web of Science ®Google Scholar
• Robins JM. Causal models for estimating the effects of weight gain on mortality. Int J Obes (Lond). 2008;32(Suppl 3):S15–S41. doi:10.1038/ijo.2008.8318695650
   PubMed Web of Science ®Google Scholar
• Naimi AI, Cole SR, Kennedy EH. An introduction to g methods. Int J Epidemiol. 2017;46(2):756–762.28039382
   PubMed Web of Science ®Google Scholar
• Dawid AP, Didelez V. Identifying the consequences of dynamic treatment strategies: a decision-theoretic overview. Stat Surv. 2010;4(none):184–231, 148. doi:10.1214/10-SS081
   Google Scholar
• Zhang Y, Young JG, Thamer M, Hernan MA. Comparing the effectiveness of dynamic treatment strategies using electronic health records: an application of the parametric g-formula to anemia management strategies. Health Serv Res. 2018;53(3):1900–1918. doi:10.1111/1475-6773.1271828560811
   PubMed Web of Science ®Google Scholar
• Keil AP, Edwards JK, Richardson DB, Naimi AI, Cole SR. The parametric g-formula for time-to-event data: intuition and a worked example. Epidemiology. 2014;25(6):889–897. doi:10.1097/EDE.000000000000016025140837
   PubMed Web of Science ®Google Scholar
• De Bruijn KMJ, Ruiter R, de Keyser CE, Hofman A, Stricker BH, van Eijck CHJ. Detection bias may be the main cause of increased cancer incidence among diabetics: results from the Rotterdam study. Eur J Cancer. 2014;50(14):2449–2455. doi:10.1016/j.ejca.2014.06.01925047425
   PubMed Web of Science ®Google Scholar
• Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol. 1995;48(12):1503–1510. doi:10.1016/0895-4356(95)00048-88543964
   PubMed Web of Science ®Google Scholar
• Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA. 1995;273(20):1605–1609. doi:10.1001/jama.1995.035204400590377745774
   PubMed Web of Science ®Google Scholar
• Forsmark CE. Incretins, diabetes, pancreatitis and pancreatic cancer: what the GI specialist needs to know. Pancreatology. 2016;16(1):10–13. doi:10.1016/j.pan.2015.11.00926795258
   PubMed Web of Science ®Google Scholar
• Andersen DK, Korc M, Petersen GM, et al. Diabetes, pancreatogenic diabetes, and pancreatic cancer. Diabetes. 2017;66(5):1103–1110. doi:10.2337/db16-147728507210
   PubMed Web of Science ®Google Scholar
• Lodi S, Phillips A, Logan R, et al. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. Lancet HIV. 2015;2(8):e335–e343. doi:10.1016/S2352-3018(15)00108-326423376
   PubMed Web of Science ®Google Scholar
• Karaboyas A, Morgenstern H, Fleischer NL, Schaubel DE, Robinson BM. Replicating randomized trial results with observational data using the parametric g-formula: an application to intravenous iron treatment in hemodialysis patients. Clin Epidemiol. 2020;12:1249–1260. doi:10.2147/CLEP.S28332133204166
   PubMed Web of Science ®Google Scholar
• Taubman SL, Robins JM, Mittleman MA, Hernan MA. Intervening on risk factors for coronary heart disease: an application of the parametric g-formula. Int J Epidemiol. 2009;38(6):1599–1611. doi:10.1093/ije/dyp19219389875
   PubMed Web of Science ®Google Scholar
• Lajous M, Willett WC, Robins J, et al. Changes in fish consumption in midlife and the risk of coronary heart disease in men and women. Am J Epidemiol. 2013;178(3):382–391. doi:10.1093/aje/kws47823813701
   PubMed Web of Science ®Google Scholar
• Garcia-Aymerich J, Varraso R, Danaei G, Camargo CA, Hernán MA. Incidence of adult-onset asthma after hypothetical interventions on body mass index and physical activity: an application of the parametric g-formula. Am J Epidemiol. 2014;179(1):20–26. doi:10.1093/aje/kwt22924107616
   PubMed Web of Science ®Google Scholar
• Jain P, Danaei G, Robins JM, Manson JE, Hernán MA. Smoking cessation and long-term weight gain in the Framingham Heart Study: an application of the parametric g-formula for a continuous outcome. Eur J Epidemiol. 2016;31(12):1223–1229. doi:10.1007/s10654-016-0200-427704230
   PubMed Web of Science ®Google Scholar
• Johnson KW, Glicksberg BS, Hodos RA, Shameer K, Dudley JT. Causal inference on electronic health records to assess blood pressure treatment targets: an application of the parametric g formula. Pac Symp Biocomput. 2018;23:180–191.29218880
   PubMedGoogle Scholar
• Lash TL, Fox MP, MacLehose RF, Maldonado G, McCandless LC, Greenland S. Good practices for quantitative bias analysis. Int J Epidemiol. 2014;43(6):1969–1985. doi:10.1093/ije/dyu14925080530
   PubMed Web of Science ®Google Scholar